USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/17079
Title: Perspectiva pentru noi biomarkeri în afectarea renală acută și cronică
Other Titles: Outlook for new biomarkers in acute and chronic renal disease
Authors: Cazan, Corina
Revenco, Ninel
Hadjiu, Svetlana
Keywords: new biomarkers;prediction;renal disease
Issue Date: 2020
Publisher: Instituţia Medico-Sanitară Publică Institutul Mamei și Copilului
Citation: CAZAN, Corina, REVENCO, Ninel, HADJIU, Svetlana. Perspectiva pentru noi biomarkeri în afectarea renală acută și cronică. In: Buletin de perinatologie. 2020, nr. 2(87), pp. 43-46. ISSN 1810-5289.
Abstract: The biological marker is defined as a measurable indicator of physiological and pathological biological processes useful in assessing the stage of the disease and the pharmacological response to therapy. The paper proposes a review of biomarkers recently involved in the early diagnosis of acute renal impairment, prognostic prediction in chronic kidney disease, glomerular nephropathy and nephrotoxicity. Clinical trials targeting biomarkers with application in monitoring the development, staging levels of severity for major adverse renal events, assess the response to therapeutic intervention, risk prediction and prognosis. In the last decade, considerable progress has been made in the discovery, development and validation of new biomarkers. Advances in biotechnology are essential for the success of clinical trials and their application in current clinical practice. A number of urinary or serum proteins, molecules and more recently microRNAs have been rigorously investigated as possible markers in acute kidney disease, chronic kidney disease, forms of glomerulonephritis and autosomal dominant polycystic kidney disease. The validation of the new biomarkers implies a long process and the implementation requires a standardized methodology, optimal cost-benefit ratio, certain efficiency for diagnosis, therapy and prognosis. Medical practice guidelines propose the combined use of new biomarkers for the improvement of clinical diagnosis, management and prognosis in renal impairment. The proposed model is the one that includes the classic predictive indicators in association with new biological or genetic markers as the only way for high quality therapeutic intervention and prognosis improvement. Biomarkers such as IL-18, NGAL, LFABP, KIM-1 can help to characterize glomerular or tubular function, interstitial injury, or inflammation. The measurement of biomarkers is possible in specialized centers with laboratories equipped to the highest technological standards and the cost-benefit aspect should not be an impediment.
metadata.dc.relation.ispartof: Buletin de perinatologie
URI: https://www.mama-copilul.md/images/buletin-perinatologic/BP_2020/BP%202%20(2020).pdf
http://repository.usmf.md/handle/20.500.12710/17079
ISSN: 1810-5289
Appears in Collections:Buletin de Perinatologie Nr. 2(87) 2020

Files in This Item:
File Description SizeFormat 
PERSPECTIVA_PENTRU_NOI_BIOMARKERI.pdf142.91 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback